Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the incidence of neutrophil engraftment after transplantation of one or two cord blood units meeting a predetermined total minimum cell dose of 2.0 x 10 to the seventh total nucleated cell (TNC)/kg.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a non-randomized, phase II protocol to evaluate engraftment of cord blood after treatment with myeloablative conditioning of fludarabine, total body irradiation and cyclophosphamide. All patients will receive tacrolimus and mycophenolate mofetil as prophylaxis for graft-vs-host disease.

Conditioning Regimen:

* Days -10 to -7: Fludarabine 30mg/m2/day IV
* Days -7 to -4: TBI 165 centigray BID
* Days -3 to -2: Cyclophosphamide 40mg/kg/day IV

Day 0: Infusion of Cord Blood Cells

Graft-vs-Host Disease Prophylaxis

* Day -1: Start tacrolimus 0.03mg/kg/day IV
* Day 0: Start MMF 7.5mg/kg IV BID

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Chronic Myeloid Leukemia Non-Hodgkin Lymphoma Myelodysplastic Syndromes

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Cord Blood Transplant Umbilical cord blood transplant Transplant Fludarabine Total Body Irradiation Cyclophosphamide

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cord Blood Transplant

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients must:

* Be between the ages of 18 and 49 years inclusive.
* Have histologically proven hematologic malignancy and must meet accepted indications for allogeneic stem cell transplantation:

* Acute myeloid leukemia (AML): high-risk in first complete remission (CR), near first CR (\< 20% marrow blasts after induction therapy), or beyond first remission.
* Acute lymphoblastic leukemia with high-risk features in first remission (Philadelphia chromosome positive or other similar high-risk features), near first CR (\< 20% marrow blasts after induction therapy), or beyond first remission.
* Chronic myeloid leukemia: in chronic phase (CP) and have failed Gleevec or are intolerant and have signs of failing other treatments, or have history of accelerated or blast phases. Storage of autologous peripheral blood stem cells is recommended for this group for patients, particularly if in chronic phase.
* Non-Hodgkin's lymphoma: aggressive histology with relapsed or primary refractory disease and not eligible for autologous transplantation. Patients with low-grade histology must have either failed 2 or more lines of systemic chemotherapy including one rituximab-based regimen. Radioimmunotherapy will be considered the equivalent of one line of chemotherapy. Excluded if prior radiotherapy to chest or prior autologous transplantation.
* Myelodysplastic syndromes with International Prognostic Scoring System (IPSS) score of 1.5 or greater.
* Other hematological malignancies if approved by the pipeline meeting on a case by case basis. Must also be approved by principal investigator.
* Have no HLA-matched or 1-antigen mismatched related donors and no HLA-matched unrelated stem cell donors, or delays involved in performing a search are likely to be detrimental to the patient.
* Have an ECOG performance status of 0 or 1 at the time of transplant.
* Have major end organs (heart, lungs, liver, and kidneys) assessed and deemed adequate to withstand the effects of high-dose therapy planned for this protocol.
* Have given voluntary informed consent.

Exclusion Criteria

Patients are ineligible for this protocol if they:

* Have a co-morbid medical condition, a psychiatric condition, or organ dysfunction that makes them at high-risk for treatment failure, for failed medical compliance, or for regimen-related toxicity from high-dose therapy.
* Patients with any of the following will be excluded:

* Pulmonary: hemoglobin (Hb)-adjusted diffusing capacity of lung for carbon monoxide (DLCO) \< 60%, forced expiratory volume in 1 second (FEV1) \< 70% of predicted, or receive continuous supplemental oxygen;
* Cardiac: left ventricular ejection fraction (LVEF) \< 50% or on any treatment for congestive heart failure;
* Renal: serum creatinine greater than 2.0 or calculated creatinine clearance \< 50 cc/min;
* Liver: ALT, AST, or serum bilirubin \> 1.5 x upper limit of normal (ULN). Any patient with elevated transaminases should have careful evaluation for the cause and liver biopsy may be required by the principle investigator. An elevated alkaline phosphatase should be fractionated and, if of liver origin, should be evaluated as for transaminases.
* Are female and are pregnant, lactating, or have a positive pregnancy test.
* Have a history of previous malignancy except for non-melanoma skin cancer and in-situ carcinoma of the cervix, unless the patient has been progression-free for \> 5 years
* Are HIV positive
* Refractory malignancy: acute leukemia with greater than 30% blasts in bone marrow unless with untreated first relapse of AML or untreated myelodysplastic syndrome evolved to AML.
* Acute leukemia with greater than 1000 blasts/ul in peripheral blood.
* Uncontrolled central nervous system (CNS) leukemia or lymphoma.
* Prior autologous or allogeneic transplantation using a myeloablative regimen.
* Uncontrolled hypertension (systolic blood pressure \[SBP\] \> 140, diastolic blood pressure \[DBP\] \> 90) or hypertension requiring \> 2 drugs for good control (SBP \< 130, DBP \< 90).
* Invasive mold infection that is uncontrolled or has received less than one month of antifungal therapy.

Minimum Eligible Age

18 Years

Maximum Eligible Age

49 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Peter McSweeney, MD

Role: PRINCIPAL_INVESTIGATOR

Colorado Blood Cancer Institute

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Rocky Mountain Blood and Marrow Transplant Program

Denver, Colorado, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Nicole Stephens, RN, BSN, OCN

Role: CONTACT

Phone: 303-336-2183

Email: [email protected]

Juli Murphy, CCRC